According to the most recent Form 13F filing that Amicus Therapeutics, Inc. made with the SEC, during the third quarter of 2018, Dupont Capital Management Corporation reduced its stake in the company by 76.3%. The company is represented on the NASDAQ market by the “FOLD.” The fund had a total of 8,856 shares of the stock in the biopharmaceutical industry before it sold 28,551 shares of the company’s stock during the quarter. After the sale, the fund’s holdings in the stock were as follows: The value of the holdings that Dupont Capital Management Corporation had made in Amicus Therapeutics was $92,000 as of the end of the most recent fiscal quarter.
Recent events have resulted in institutional investors and other hedge funds reevaluating the positions they had previously held in the company and making appropriate adjustments. A new investment of $27,000 was made during the third quarter by China Universal Asset Management Co. Ltd. in the pharmaceutical company Amicus Therapeutics. First Horizon Advisors, Inc. invested in Amicus Therapeutics $29,000 during the second quarter of 2018. During the second quarter, Lazard Asset Management LLC accomplished an increase of 68.0% in the proportion of Amicus Therapeutics stock that it owned. Lazard Asset Management LLC now holds 9,837 shares of the biopharmaceutical company’s stock after purchasing an additional 3,981 shares during the most recent quarter. Each share of the biopharmaceutical company’s stock is currently valued at $105,000. The second quarter saw Strs Ohio make a new investment in Amicus Therapeutics for a total value of $122,000. During the second quarter, Assetmark Inc. increased the percentage of ownership it holds in Amicus Therapeutics by 353.0%. This was done so that the company would not be outdone. Assetmark Inc. now has 12,027 shares in the biopharmaceutical business after purchasing an additional 9,372 shares during the most recent quarter to bring their total number to 12. These shares are currently worth $129,000 at the current market price.
When trading started on Thursday, the price of a share of FOLD was $13.10 per share. Amicus Therapeutics, Inc. has seen its share price go as low as $5.91 and as high as $13.61 over the past year. The company has a price-to-earnings ratio of -14.24, a market capitalization of $3.68 billion, and a beta value of 0.88. The price-to-earnings ratio measures how much an asset is worth relative to its current price. The debt-to-equity ratio is 2.95, the current ratio is 2.78, and the quick ratio is 2.70. All of these figures are presented in ratio form. The stock has been trading at $11.88 on average over the past 50 trading days, while its simple moving average over the past 200 trading days is $11.30.
Amicus Therapeutics (NASDAQ: FOLD) made public on Monday, November 7, the quarterly financial figures that the company had worked on for the previous few weeks. The biopharmaceutical company announced earnings per share for the quarter of $0.12, which was $0.07 higher than the consensus expectation of $0.19. The Utica Company announced earnings per share for the quarter of $0.12, which was $0.07 higher than the consensus expectation of $0.19. The company’s sales for the quarter came in at $81.69 million, which is significantly lower than the consensus projection of $84.55 million made by financial analysts. The return on equity for Amicus Therapeutics was negative by 123.94 percent, and the company’s net margin was negative by 81.65 percent. The majority opinion held by market analysts is that Amicus Therapeutics, Inc. will end the current fiscal year with a loss of $0.77 per share.
In related news, on January 13, Director Margaret G. Mcglynn sold 15,000 shares of the company’s stock. This is just one of the latest developments about this subject. When all the shares were finally put up for sale, they brought in a total of $195,450.00, corresponding to an average price of 13.03 dollars each. As a result of the successful completion of the transaction, the director is now the owner of 50,705 shares of the company, which have a combined value of $660,686.15. The United States Securities and Exchange Commission was given legal documents about the transaction, which can be viewed at this location. On November 1, Amicus Therapeutics CEO Bradley L. Campbell reportedly sold 5,470 shares of the company’s stock, as stated in other announcements by the business. The average price paid for each share was $10.01, and the total amount received for the shares was $54,754.70. After considering the purchase, the company’s chief executive officer now has a direct ownership stake of 689,618 shares, which at the moment have a value of approximately $6,903,076.18. After clicking on this link, you will be taken to the SEC filing, where the transaction was described in greater detail. In addition, Margaret G. Mcglynn, a director of the company, sold a total of 15,000 shares of the company’s stock on Friday, January 13. It was determined that 13.03 dollars were the price that was paid on average for each share, and a total of $195,450.00 worth of the stock was traded. After the completion of the transaction, the director is now the owner of 50,705 shares in the company. The total value of these shares is $660,686.15, making the director the owner of 50,705 shares. The disclosure about the purchase can be found i